Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 16/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3041153 | 0.80 | EGLN2 (0.36) | EGLN2PDE10AALDH1A1KDM4E | |
| SCHEMBL21731043 | 0.80 | EGLN2 (0.38) | EGLN2PDE10A | |
| SCHEMBL13359561 | 0.80 | ALDH1A1 (0.47) | EGLN2ALDH1A1KDM4E | |
| SCHEMBL9085326 | 0.77 | EGLN2 (0.33) | EGLN2PDE10AALDH1A1KDM4E | |
| SCHEMBL3041274 | 0.76 | EGLN2 (0.35) | EGLN2PDE10AALDH1A1KDM4E | |
| SCHEMBL31073488 | 0.70 | PDE2A (0.34) | EGLN2 | |
| SCHEMBL3603671 | 0.70 | EGLN2 (0.56) | EGLN2ALDH1A1KDM4E | |
| SCHEMBL3604227 | 0.69 | KDM4E (0.51) | EGLN2ALDH1A1KDM4E | |
| SCHEMBL18077066 | 0.68 | EGLN2 (0.43) | EGLN2PDE10AKDM4E | |
| SCHEMBL3134115 | 0.68 | EGLN2 (0.45) | EGLN2PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326754-A1 | DNA-PK Inhibitor Compounds and Uses Thereof | ADMARE THERAPEUTICS SOC (CA) | 2025-10-23 | — | — | US | disclosed |
| EP-4522620-A1 | DNA-PK INHIBITOR COMPOUNDS AND USES THEREOF | Admare Therapeutics Society (CA) | 2025-03-19 | — | — | EP | disclosed |
| CN-118619945-A | KIF18A inhibitors and uses thereof | 诺沃斯达药业(上海)有限公司 | 2024-09-10 | — | — | CN | disclosed |
| WO-2023215991-A1 | DNA-PK INHIBITOR COMPOUNDS AND USES THEREOF | adMare Therapeutics Society (CA) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023215991-A1 | DNA-PK INHIBITOR COMPOUNDS AND USES THEREOF | adMare Therapeutics Society (CA) | 2023-11-16 | — | — | WO | disclosed |
| US-11117899-B2 | [1,2,4]triazolo[1,5-c]pyrimidine derivative as A2A receptor inhibitor | MEDSHINE DISCOVERY INC. (CN) | 2021-09-14 | — | — | US | disclosed |
| US-11066411-B2 | — | — | 2021-07-20 | — | — | US | disclosed |
| US-20200131184-A1 | [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE DERIVATIVE AS A2A RECEPTOR INHIBITOR | MEDSHINE DISCOVERY INC. (CN) | 2020-04-30 | — | — | US | disclosed |
| US-9051323-B2 | Substituted imidazopyrimidines and triazolopyrimidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-06-09 | — | — | US | disclosed |
| US-9051323-B2 | Substituted imidazopyrimidines and triazolopyrimidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-06-09 | — | — | US | disclosed |
| US-20100216765-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | disclosed |
| US-7713973-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-11 | — | — | US | disclosed |
| US-7713973-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-11 | — | — | US | disclosed |
| US-20100113441-A1 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-06 | — | — | US | disclosed |
| US-20100113441-A1 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-06 | — | — | US | disclosed |
| US-20100113441-A1 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-06 | — | — | US | disclosed |
| WO-2008113469-A2 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-09-25 | — | — | WO | disclosed |
| EP-1812439-A2 | KINASE INHIBITORS | Takeda San Diego, Inc. (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006044687-A2 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20060084650-A1 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084650-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | EGLN2 2254/4885PDE10A 887/4885ALDH1A1 4068/4885 |
| US-20100216765-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | EGLN2 2254/4885PDE10A 887/4885ALDH1A1 4068/4885 |
| US-11117899-B2 | [1,2,4]triazolo[1,5-c]pyrimidine derivative as A2A receptor inhibitor | ADORA2A, ADORA1, ADORA3 | EGLN2 3884/4885PDE10A 337/4885ALDH1A1 505/4885 |
| US-11066411-B2 | — | ADORA2A, ADORA1, ADORA2B | EGLN2 3167/4885PDE10A 412/4885ALDH1A1 494/4885 |
| US-20100113441-A1 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | TYMP, DPYD, THPO | EGLN2 1710/4885PDE10A 4405/4885ALDH1A1 2118/4885 |
| US-20200131184-A1 | [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE DERIVATIVE AS A2A RECEPTOR INHIBITOR | ADORA2A, ADORA1, ADORA3 | EGLN2 3884/4885PDE10A 337/4885ALDH1A1 505/4885 |
| US-20250326754-A1 | DNA-PK Inhibitor Compounds and Uses Thereof | DCK, CHEK1, CHEK2 | EGLN2 1640/4885PDE10A 1697/4885ALDH1A1 2823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.